The effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of glipizide in Chinese subjects
文献类型：期刊论文
| 作者 | Tan, Bo1; Zhang, Yi-Fan1 ; Chen, Xiao-Yan1; Zhao, Xiao-Hua1; Li, Guo-Xin2; Zhong, Da-Fang1
|
| 刊名 | EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
 |
| 出版日期 | 2010-02 |
| 卷号 | 66期号:2页码:145-151 |
| 关键词 | Glipizide CYP2C9 CYP2C19 Genetic polymorphism Pharmacokinetics Pharmacodynamics |
| ISSN号 | 0031-6970 |
| DOI | 10.1007/s00228-009-0736-2 |
| 文献子类 | Article |
| 英文摘要 | Objective To study the effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of glipizide. Methods Eighteen healthy male subjects were divided into three groups according to their genotypes: group I, CYP2C9*1/*1 and CYP2C19 extensive metabolizers (EMs); group II, CYP2C9*1/*1 and CYP2C19 poor metabolizers (PMs); and group III, CYP2C9*1/*3 and CYP2C19 EMs. After a single dose of a 5-mg glipizide tablet, plasma concentrations of glipizide for a 36-h period were determined. Meanwhile, plasma glucose levels and plasma insulin levels were determined from 0 to 4 h after dosing. Results The area under the plasma concentration-time curve (AUC(0-infinity)) was 2.0-fold higher and the oral clearance was 51.1% lower in group III than in group I. The change in fasting insulin level within 1 h (Delta AUEC(insulin0-1h)) in group III was 3.8-fold higher than that in group I. The glipizide parameters in group II exhibited similar tendencies to those in group III. Conclusions These results suggest that CYP2C9 polymorphism significantly influences the pharmacokinetics and pharmacodynamics of glipizide, which needs to be considered in clinical practice. CYP2C19 polymorphism exhibits a tendency to influence the effects of glipizide, to a certain extent similarly to CYP2C9 polymorphism. |
| WOS关键词 | METABOLISM ; GLIBENCLAMIDE ; GENOTYPE |
| 资助项目 | Natural Science Foundation of China[30772621] |
| WOS研究方向 | Pharmacology & Pharmacy |
| 语种 | 英语 |
| WOS记录号 | WOS:000274022300005 |
| 出版者 | SPRINGER HEIDELBERG |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/278981]  |
| 专题 | 上海药物代谢研究中心 |
| 通讯作者 | Zhong, Da-Fang |
| 作者单位 | 1.Chinese Acad Sci, Shanghai Inst Mat Med, Shanghai 201203, Peoples R China; 2.Liaoning Univ Tradit Chinese Med, Affiliated Hosp 2, Dept Clin Pharmacol, Shenyang 110034, Peoples R China |
| 推荐引用方式 GB/T 7714 | Tan, Bo,Zhang, Yi-Fan,Chen, Xiao-Yan,et al. The effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of glipizide in Chinese subjects[J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY,2010,66(2):145-151. |
| APA | Tan, Bo,Zhang, Yi-Fan,Chen, Xiao-Yan,Zhao, Xiao-Hua,Li, Guo-Xin,&Zhong, Da-Fang.(2010).The effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of glipizide in Chinese subjects.EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY,66(2),145-151. |
| MLA | Tan, Bo,et al."The effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of glipizide in Chinese subjects".EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY 66.2(2010):145-151. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。